Ascendis Pharma A (ASND) Capital Expenditures (2012 - 2024)

Ascendis Pharma A has disclosed Capital Expenditures across 13 years of filings, most recently posting -$512868.5 for Q3 2024.

• Capital Expenditures for Q3 2024 came in at -$512868.5, up 51.73% year-over-year; the trailing twelve-month figure through Sep 2024 was -$1.0 million (up 84.33% YoY), and the FY2023 annual result was -$2.6 million, up 82.23% from the prior year.
• Capital Expenditures came in at -$512868.5 for Q3 2024 at Ascendis Pharma A, down from -$368295.6 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $48.7 million in Q4 2021 to a low of -$13.3 million in Q3 2021.
• The 5-year median for Capital Expenditures is -$3.2 million (2022), against an average of $1.7 million.
• Peak annual rise in Capital Expenditures reached 315.62% in 2020, while the deepest fall reached 1344.86% in 2020.
• Ascendis Pharma A's Capital Expenditures stood at $42.3 million in 2020, then climbed by 15.31% to $48.7 million in 2021, then plunged by 107.92% to -$3.9 million in 2022, then surged by 101.76% to $67784.2 in 2023, then plunged by 856.62% to -$512868.5 in 2024.
• The last three Capital Expenditures figures came in at -$512868.5 (Q3 2024), -$368295.6 (Q2 2024), and -$216186.0 (Q1 2024), per Business Quant data.